Detransitioner Bill of Rights
Detransitioner Bill of Rights
(a) The State has a compelling government interest in protecting the health and safety of its citizens,
especially vulnerable children and adolescents.
(b) Some individuals, including those who are under the age of 18, may experience discordance between
their sex and their perception of their sex or between their sex and their perception of their gender,
which may lead to psychological distress. Only a small percentage of the American population
experience distress identifying with their biological sex.
(c) The cause of a discordance between sex and perceived sex or between sex and perceived gender is not
definitively known, and the diagnosis is based primarily on the individual’s self-evaluation. But there
is evidence that peer groups and psychological maladaptive coping mechanisms can influence and
exacerbate this perceived condition.
donoharmmedicine.org
(d) Individuals struggling with distress related to a discordance between their perception and their sex often
also experience co-occurring psychopathology preceding their gender discordance, which indicates
that these individuals could benefit greatly from mental health services that address comorbidities and
the underlying causes of their distress before undertaking any hormonal or surgical intervention.
(e) Individuals with autism spectrum disorder (ASD) are particularly likely to report struggling with distress
related to a discordance between their perception and their sex. The overlapping symptoms of ASD
and gender dysphoria or gender incongruence increases the risk of diagnostic overshadowing and
makes false positives in the diagnosis of an incongruence between sex and perceived sex or between
sex and perceived gender more likely.
(f) Interventions for a minor who expresses a desire to appear as a sex different from his or her own—
including social, medical, and surgical interventions—can create a process whereby the interventions
themselves can contribute to a discordance between the minor’s perceived sex or perceived gender
and the minor’s sex.
(g) Taking a wait-and-see approach to prepubertal minors who reveal signs of discordance, sometimes
called “watchful waiting,” results in a majority of those minors coming to terms with their bodies
and accepting the reality of their sex by late adolescence or early adulthood. Puberty is an identity-
clarifying event: the development of physical features and emergence of sexual desire are strongly
associated with consolidation in one’s understanding of one’s sex.
(h) Recent years have seen a rising number of individuals known as detransitioners who were initially
subjected to physiological interventions to alter their appearance and bodily functions to align with
their perceived sex or perceived gender but who later experienced a resolution of any inconsistency
between their sex and their perceived gender or perceived sex. Some of these individuals indicate
that they were pressured to medically transition in the first place. Many of these individuals regret
the decision to transition and regret the physical harm the interventions caused. Many individuals do
not detransition or express regret until adulthood. The total percentage of people who experience this
regret is unknown.
(i) Detransitioners were subjected to an experimental course of treatment to alter their bodies to align
with their perceived sex or their perceived gender.
(1) Health authorities in Sweden, Finland, and the U.K. have conducted systematic reviews of evidence
and, having found no reliable evidence that the benefits of these physiological interventions
outweigh the risks, these countries have decided to place severe restrictions on gender transition
procedures for minors. They now recommend psychotherapy as a first, and ideally only, line of
treatment for youth with gender dysphoria.
(2) Despite the course reversal underway in Europe, some in the American medical community
are aggressively pushing for interventions on minors that medically alter the minor’s hormonal
balance and remove healthy external and internal sex organs. Organizations that advocate for such
interventions, including the World Professional Association for Transgender Health (WPATH),
do so for ideological rather than scientific or medical reasons and actively stifle dissent in the
medical community. This is the opposite of the open, honest, and good-faith discussion needed
for ensuring science-based medicine, which is especially needed for a novel treatment paradigm
for minors.
(3) Medical organizations and doctors who defer to organizations like WPATH greatly exaggerate the
(j) The physiological aspect of this course of treatment commonly begins when doctors administer long-
acting GnRH agonists (puberty blockers) to delay the natural onset or progression of puberty.
(1) This use of puberty blockers to treat minors whose perceived gender or perceived sex is
inconsistent with the minor’s sex is experimental and is off-label use, meaning it is not approved
by the FDA.
(2) The suspected side effects of puberty blockers include severely diminished bone density, cognitive
impairment, brain swelling that can lead to blindness, and infertility, especially if followed by
cross-sex hormones or surgeries. There is reason to suspect puberty blockers may also have
permanent negative effects on adult sexual function.
(3) Because puberty blockers have never been subjected to randomized controlled trials in their use
for gender dysphoria, there are no reliable data on their long-term risks.
(k) After puberty blockade, or even sometimes without it, treatment involves administering “cross-
sex” hormonal treatments that induce the development of secondary sex characteristics commonly
associated with the opposite sex, including the development of breasts and wider hips in male minors
taking estrogen and the development of greater muscle mass, bone density, body hair, and a deeper
voice in female minors taking testosterone.
(A) For males, these risks may include irreversible infertility; thromboembolic disease, including
blood clots; cholelithiasis, including gallstones; coronary artery disease, including heart attacks;
Type 2 diabetes; breast cancer; macroprolactinoma, which is a tumor of the pituitary gland;
cerebrovascular disease, including strokes; depression; and hypertriglyceridemia, which is an
elevated level of triglycerides in the blood.
(B) For females, these risks may include irreversible infertility; sever liver dysfunction; coronary
artery disease, including heart attacks; increased risk of breast, cervical, and uterine cancers;
cerebrovascular disease, including strokes; hypertension; erythrocytosis, which is an increase
in red blood cells; sleep apnea; Type 2 diabetes; loss of bone density; elevated rates of aggression;
depression; and destabilization of psychiatric disorders.
(2) Although proponents of puberty blockers argue that these drugs are “fully reversible” and merely
give users a “window of time” to decide whether to proceed with the transition, research indicates
that virtually all minors put on puberty blockers continue on to take cross-sex hormones. While
advocates of using puberty blockers for this purpose believe this fact is evidence that clinicians
(l) The final phase of treatment often calls for the individual to undergo surgical procedures to create
an appearance similar to that of the opposite sex. These procedures may include “top surgery,” a
euphemism for bilateral mastectomy, a surgical procedure that entirely removes a female’s breasts, and
“bottom surgery,” a euphemism for surgical procedures that include the removal of a minor’s healthy
reproductive organs and the creation of an artificial form aiming to approximate the appearance of the
genitals of the opposite sex.
(1) Other countries, including Sweden and Finland, do not allow these surgeries to take place before
age 18. In the United States, “top” and “bottom” surgeries for minors have increased in recent
years but remain relatively uncommon. The World Professional Association for Transgender
Health recently eliminated surgery-related age minimums from its standards of care (with the
exception of phalloplasty).
(2) These types of surgical procedures include several irreversible invasive procedures for males and
females that involve the alteration of biologically healthy and functional body parts.
(A) For males, surgery may include a penectomy, which is the removal of the penis; orchiectomy,
which is the removal of the testicles; vaginoplasty, which is the construction of a vagina-
like structure, typically through a penile inversion procedure; clitoroplasty, which is the
construction of a clitoris-like structure; and vulvoplasty, which is the construction of a vulva-
like structure.
(B) For females, surgery may include a hysterectomy, which is the removal of the uterus;
oophorectomy, which is the removal of the ovaries; vaginectomy, which is the removal of the
vagina; reconstruction of the urethra; metoidioplasty or phalloplasty, which is the construction
of a penis-like structure; scrotoplasty, which is the construction of a penis-like and scrotum-
like structure; and implantation of erection or testicular prostheses.
(3) The risks, complications, and long-term concerns associated with these types of procedures for
both males and females are not entirely known, but they may include fistulas, chronic infection,
the need for a colostomy, atrophy, and complete loss of sensation, sexual or otherwise. When
performed on a male who underwent puberty suppression, for example, vaginoplasty typically
requires the borrowing of tissue from the colon to create a “neovagina.” The creation of a
second surgical site is associated with a far higher risk of infection and additional complications,
including a risk of death.
(4) Non-genital surgeries also include various invasive procedures for males and females that involve
the alteration or removal of biologically normal and functional body parts.
(A) For males, this non-genital surgery may include augmentation mammoplasty; facial feminization
surgery; voice feminization surgery; thyroid cartilage reduction; gluteal augmentation; hair
reconstruction; and other aesthetic procedures.
(B) For females, this non-genital surgery may include a subcutaneous mastectomy; voice
masculinization surgery; pectoral implants; and other aesthetic procedures.
(n) Because the “gender affirming” model of treatment is relatively new, there are no adequate studies on
rates of detransition and regret among the cohort that received treatment in line with this model. Claims
about detransition and regret being “extremely rare” are based on studies on adults who transitioned
as adults or minors who were transitioned under highly restrictive and controlled conditions. Such
claims ignore other methodological problems in the research, including high dropout rates and very
short follow-up times. Published research is also tainted by politicized efforts to ignore or sanitize
the concept of detransitioning. For example, some advocates of the “affirming” model claim that
most regret and examples of detransition are due to “internalized transphobia” or “minority stress.”
Finally, some research suggests that most detransitioners do not inform gender clinics that they have
detransitioned, which may be because they fear backlash from their providers or do not trust their
medical judgment.
(o) There is also a concerning lack of treatment guidelines for the medical care of detransitioners. In
the absence of a protocol for the treatment of detransitioners, individuals undergoing detransition
experience unmet healthcare needs. Detransitioners report a dearth of information about ceasing
hormonal treatments and frequently encounter clinicians who are poorly informed about medical
detransition. In addition, some jurisdictions have mandated insurance coverage for gender transition
procedures but have refused to extend this mandate to detransition procedures.
(2) Research ways to help detransitioners and those who regret undergoing gender transition
procedures; and
(3) Develop evidence-based standards for treating detransitioners and supporting detransitioners as
well as those who regret undergoing gender transition procedures.
SECTION 2. DEFINITIONS
(b) “Sex” means the biological indication of male and female in the context of reproductive potential or
capacity, such as sex chromosomes, naturally occurring sex hormones, gonads, and nonambiguous
internal and external genitalia present at birth, including secondary sex characteristics, without regard
to an individual’s psychological, chosen, or subjective experience of gender.
(c) “Female” means an individual who has, had, will have, or would have but for a developmental or genetic
anomaly or historical accident, the reproductive system that at some point produces, transports, and
utilizes eggs for fertilization.
(e) “Gender” means the psychological, behavioral, social, and cultural aspects of being male or female.
(h) “Gender dysphoria” is the diagnosis of Gender Dysphoria under the Diagnostic and Statistical Manual
of Mental Disorders, Fifth Edition (DSM-5).
(i) “Gender incongruence” is the diagnosis under the World Health Organization’s International
Classification of Diseases, Eleventh Edition (ICD-11).
(j) “Gender transition procedure” means any pharmaceutical or surgical intervention to alter an individual’s
body as a treatment to address an inconsistency between a minor’s sex and minor’s perceived gender
or perceived sex.
(k) “Gender clinic” means a healthcare entity that provides or prescribes gender transition procedures or
refers individuals for gender transition procedures.
(l) “Detransitioner” means (1) an individual who began or completed a gender transition procedure but
later sought treatment to reverse the effects of the gender transition procedure due to the resolution
of any inconsistency between the individual’s sex and the individual’s perceived sex or perceived
gender, or (2) an individual who began a gender transition procedure but has ceased that procedure
due to the resolution of any inconsistency between the individual’s sex and the individual’s perceived
sex or perceived gender.
(m) “Detransition procedure” means any treatment, including mental-health treatment, medical
interventions, and surgeries that (1) stop or reverse the effects of a prior gender transition procedure
due to the resolution of any inconsistency between the individual’s sex and the individual’s perceived
sex or perceived gender, or (2) help an individual cope with the effects of a prior gender transition
procedure after the resolution of any inconsistency between the individual’s sex and the individual’s
perceived sex or perceived gender.
(n) “Healthcare professional” means a person who is licensed, certified, or otherwise authorized by the
laws of this State to administer healthcare in the ordinary course of the practice of his or her profession.
(o) “Mental health professional” means a person who is licensed to diagnose and treat mental health
conditions in this State.
(p) “Physician” means a person who is licensed to practice medicine in this State.
(a) No healthcare professional or physician may provide pharmaceutical or surgical treatment to minors
to address an inconsistency between the minor’s sex and the minor’s perceived gender or perceived
sex unless the healthcare professional or physician has obtained informed consent from the minor and
the minor’s parent(s) or legal guardian(s).
(1) No reliable studies have shown that these treatments reduce the risk of suicide in children or
adolescents with gender dysphoria.
(2) The Federal Food & Drug Administration has not approved the use of puberty blockers or cross-
sex hormones for the purpose of treating gender dysphoria or gender incongruence. In other
words, using these medications to treat gender dysphoria or gender incongruence is considered
“off-label” use because they are not being used for their approved purpose.
(3) European governments, including the United Kingdom, Sweden, and Finland, have studied these
treatments and have concluded there is no reliable evidence showing that the potential benefits of
puberty blockers and cross-sex hormones for this purpose outweigh the risks. Those governments
instead recommend psychotherapy as the first line of treatment for children and adolescents with
gender dysphoria.
(4) The use of puberty blockers and cross-sex hormones for this purpose increases the risk of your
child or adolescent being sterilized, meaning that he or she will never be able to have children.
(5) The use of puberty blockers and cross-sex hormones for this purpose carry numerous other risks
of physical harm, including severely decreased bone density, heart disease, stroke, and cancer.
(6) The effect of these treatments on the brain development of your child or adolescent is entirely
unknown.
(1) The healthcare professional or physician has engaged in unprofessional conduct and is subject
to discipline by the appropriate licensing entity or disciplinary review board with competent
jurisdiction in this state. That discipline must include suspension of the ability to administer
healthcare or practice medicine for at least one year.
(2) The parent(s) or legal guardian(s) of the minor subject to the violation shall have a private cause
of action for damages and such equitable relief as the court may determine is justified. The court
may also award reasonable attorney’s fees and court costs to a prevailing party.
(d) Notwithstanding any contrary provision of law, no healthcare professional or physician may deny a
parent or legal guardian access to the medical records or medical information relating to the parent’s
or legal guardian’s minor.
(1) This subsection shall not require a person to provide access when:
(A) The medical records or medical information relate to harm resulting from abuse, neglect, or
domestic violence;
(B) The person denying access reasonably believes the parent or legal guardian is responsible for
the abuse, neglect, or other injury resulting from domestic violence; and
(C) The person denying access reasonably believes that informing the parent or legal guardian
would not be in the best interests of the minor.
(A) A parent’s or legal guardian’s refusal to permit the parent’s or legal guardian’s minor to seek
a gender-transition procedure to address an inconsistency between the minor’s sex and the
minor’s perceived gender or perceived sex;
(B) A parent’s or legal guardian’s refusal to address the parent’s or legal guardian’s minor using
pronouns that are inconsistent with the minor’s sex; or
(C) A parent’s or legal guardian’s refusal to address the parent’s or legal guardian’s minor with a
name other than the minor’s legal name.
(3) Any parent or legal guardian who is denied access to medical records or medical information in
violation of this subsection shall have a private cause of action for damages and such equitable
relief as the court may determine is justified. The court may also award reasonable attorney’s fees
and court costs to a prevailing party.
(e) The Attorney General may investigate a potential violation of this section, may seek production of
documents or testimony through a civil investigative demand, and may bring an action to enforce
compliance with this section.
(a) No city, municipality, or locality may prohibit the provision of mental-health therapy to help a minor
address an inconsistency between the minor’s sex and the minor’s perceived gender or perceived sex.
(b) No city, municipality, or locality may prohibit a parent or legal guardian from consenting to, or
withholding consent from, the provision of mental-health therapy to help a minor address an
inconsistency between the minor’s sex and the minor’s perceived gender or perceived sex.
(a) Any gender clinic operating in the State must provide a report of statistics regarding all gender
transition procedures to [State Health Agency].
(b) [State Health Agency] shall develop a form for this purpose and determine the statistics to be reported,
which must include the following:
(1) The date on which the gender transition procedure was prescribed or the referral was made for
the gender transition procedure;
(2) The age and sex of the person to whom the gender transition procedure was prescribed or for
whom the gender transition procedure referral was made;
(3) For any drug prescribed as part of a gender transition procedure, the (A) name of the drug; (B)
the dosage; (C) the dosage frequency and duration; and (D) the method by which the drug will be
administered;
(4) For any surgical procedure provided, or any referral made for a surgical procedure, as part of a
gender transition procedure, the type of surgical procedure, identified by CPT code;
(6) The name, contact information, and medical specialty of the medical provider who prescribed the
gender transition procedure or made the referral for the gender transition procedure.
(7) A description of any other neurological, behavioral, or mental health conditions that the person has
been diagnosed with or exhibits symptoms of, including Autism Spectrum Disorder, depression,
anxiety, or bi-polar disorder.
(1) Completed by each gender clinic at which a gender transition procedure is prescribed or a referral
is made for a gender transition procedure;
(2) Signed by the medical provider or healthcare professional who prescribes the gender transition
procedure or makes a referral for a gender transition procedure; and
(3) Transmitted by the gender clinic to the [Agency] within 15 days after the end of the calendar
month during which the gender transition procedure was prescribed or the referral was made for
a gender transition procedure.
(d) Reporting forms required under this Section shall not contain any of the following regarding the person
receiving a gender transition procedure or a referral for a gender transition procedure:
(2) Common identifiers of the person, including a Social Security number or a driver’s license number;
or
(3) Any other information not required under this Section that would make it possible to identify the
person.
(e) The [Agency] shall prepare a comprehensive annual statistical report for the Legislature based upon the
data gathered from forms submitted under this Section. This report shall include a detailed summary
of the information obtained under this Section. The report shall not disclose the identity of any person
or entity that is the subject of any report. The statistical report shall also be made independently
available to the public by the [Agency] in a downloadable format.
(f) If any healthcare professional or physician fails to comply with this Section:
(1) The healthcare professional or physician has engaged in unprofessional conduct and is subject
to discipline by the appropriate licensing entity or disciplinary review board with competent
jurisdiction in this state. That discipline must include suspension of the ability to administer
healthcare or practice medicine for at least one year.
(2) The gender clinic where the healthcare professional or physician is employed shall pay a civil fine
not to exceed [[$250,000]].
(g) The Attorney General may investigate a potential violation of this section, may seek production of
documents or testimony through a civil investigative demand, and may bring an action to enforce
compliance with this section.
(a) Any gender clinic that uses State funds to directly or indirectly provide or pay for the performance of
gender transition procedures must, as a condition of receiving such funds, agree to provide or pay for
the performance of detransition procedures.
(b) If any insurance policy includes coverage for gender transition procedures, the policy must also include
coverage for detransition procedures.
(c) Any entity providing insurance coverage for detransition procedures must provide statistics in a form
created by [State Health Agency] regarding insurance claims for detransition procedures in the State.
(d) [State Health Agency] shall develop a form for the purpose of subsection 5(c). That form must require
reporting of the following:
(2) The age and sex of the individual receiving the detransition procedure;
(3) If known, the date that the individual initially began a prior gender transition procedure;
(4) The state and county of residence of the person receiving the gender transition procedure;
(e) The form completed pursuant to this Section shall be transmitted by the gender clinic to the [Agency]
within 15 days after the end of the calendar month during which the claim for the detransition procedure
was filed.
(f) Reporting forms required under this Section shall not contain any of the following regarding the
person receiving a detransition procedure:
(2) Common identifiers of the person, including a Social Security number or a driver’s license number;
or
(3) Any other information not required under this Section that would make it possible to identify the
person.
(g) The [Agency] shall prepare a comprehensive annual statistical report for the Legislature based upon the
data gathered from forms submitted under this Section. This report shall include a detailed summary
of the information obtained under this Section. The report shall not disclose the identity of any person
or entity that is the subject of any report. The statistical report shall also be made independently
available to the public by the [Agency] in a downloadable format.
(h) The Attorney General may investigate a potential violation of this section, may seek production of
documents or testimony through a civil investigative demand, and may bring an action to enforce
compliance with this section..
(a) Within [[30]] days of the effective date of this Act, [[State Records Agency]] shall develop an expedited
process for changing the sex, name, pronouns, and any other information recorded on birth certificates,
driver’s licenses, or other legal documents when such information had been previously changed to
align with an individual’s perception of his or her gender or sex when that perception was inconsistent
with the individual’s sex.
(b) The requirement of a court order for changing certain legal documents under Section [[state code
section governing changes to legal documents]] is waived for changes made pursuant to subsection (a).
(c) To facilitate the expedited process in subsection (a) and the waiver of a court order in subsection (b),
[[State Records Agency]] shall maintain copies of original legal documents when those documents are
changed to align with an individual’s perception of his or her gender or sex when that perception is
inconsistent with the individual’s sex.
(a) Any healthcare professional or physician who provides a minor with a gender transition procedure is
strictly and personally liable for all costs associated with subsequent detransition procedures sought
by the minor within 25 years after the commencement of a gender transition procedure.
(b) Any individual who undergoes a detransition procedure may bring a civil action either within 25
years from the day the person reaches 18 years of age or within 4 years from the time the cost of
a detransition procedure is incurred, whichever date is later, against a healthcare professional or
physician as described in subsection (a) in a court of competent jurisdiction for:
(c) Any healthcare professional or physician who provides a minor with a gender transition procedure
is strictly liable to that minor if the treatment or the after-effects of such treatment, including a
subsequent detransition procedure, results in any injury, including physical, psychological, emotional,
or physiological harms, within the next 25 years.
(d) A person who suffers an injury described in subsection (c) (or a representative, including a legal
guardian, on behalf of such person) may bring a civil action either within 25 years from the day the
person reaches 18 years of age or within 4 years from the time of discovery by the injured party of both
the injury and the causal relationship between the treatment and the injury, whichever date is later,
against the offending healthcare professional or physician in a court of competent jurisdiction for:
(2) compensatory damages, including but not limited to pain and suffering, loss of reputation, loss of
income, and loss of consortium, which includes the loss of expectation of sharing parenthood;
(1) If at the time the person subjected to treatment attains the age of 18-years old, he or she is under
other legal disability, the limitation period in subsections (b) and (d) does not begin to run until the
removal of the disability;
(2) The limitation period in subsections (b) and (d) does not run during a time period when the
individual is subject to threats, intimidation, manipulation, fraudulent concealment, or fraud
perpetrated by the physician or other healthcare professional who provided the treatment
described in subsections (a) or (c), or by any person acting in the interest of the physician or other
healthcare professional.
(f) A healthcare professional or physician may not seek a contractual waiver of the liability in subsections
(a) or (c). Any attempted waiver is contrary to the public policy of this State and is null and void.
(g) Section [[state code section governing tort damage caps]] does not apply to actions for damages under
this section.
(h) The Attorney General may investigate a potential violation of this section, may seek production of
documents or testimony through a civil investigative demand, and may bring an action to enforce
compliance with this section.
(i) This section does not deny, impair, or otherwise affect any right or authority of the Attorney General,
the State of [[State]], or any agency, officer, or employee of the State, acting under any law other than
this section, to institute or intervene in any proceeding.
SECTION 9. SEVERABILITY
(a) To the extent the State or any private party is enjoined from enforcing any part or application of
any section in this statute, all other parts or applications of that section and all other sections are
severable and enforceable. It is the Legislature’s intent that any lawful section, application, or part
of a section remain enforceable no matter the number of sections, parts of sections, or applications
deemed unenforceable. Under no circumstance should a court conclude the Legislature intended that
the State or private party be enjoined from enforcing any section, application, or part of a section not
deemed independently unenforceable.
(a) This Act shall take effect immediately, the public welfare requiring it.
donoharmmedicine.org